Under the trend of medical reform, the withdrawal of drugs from the network has become the norm, and a large number of drugs will be discontinued

"Pharmaceutical Network Industry Dynamics" October 27, Gansu Provincial Public Resources Trading Bureau issued "on the application for the withdrawal of waste drugs to cancel the qualification of the winning bid hanging network related matters notice" pointed out that 32 pharmaceutical companies recently due to production line transformation, rising costs, shortage of raw materials, discontinuation and other reasons to submit applications for the withdrawal of waste drugs.
According to combing, 32 pharmaceutical companies withdrew a total of 46 drugs, including injections of sodium aweicate, bao coughingin particles, rhinitis tablets, buprenorphine tablets, metformin hydrochloric acid tablets, compound cloonest tablets Throat hydrants, compound renitin capsules, serotonin tablets, sulphate pills, tyfur fluorine injections, psychic capsules, blood plug-through particles, ginkgo blades, etc., both commonly used traditional Chinese medicine, but also common chemicals.
, 16 of the drugs were noted for discontinuation.
fact, pharmaceutical enterprises take the initiative to apply for product revocation of the internet, is a common phenomenon in the pharmaceutical industry in recent years.
According to incomplete statistics, since this year, Jiangxi, Sichuan, Chongqing, Hainan, Fujian, Henan, Gansu, Liaoning, Heilongjiang, Yunnan, Jiangxi and other local drug regulatory bureaus have issued a pharmaceutical company announced the suspension of production, suspension or closure of business activities.
such as January 8, Hainan Province Pharmaceutical Centralized Procurement Center issued "on the publicity of part of the drug withdrawal notice (2020.01.08)", there are 250 drug applications to cancel the network.
In which it is clearly stated that 171 drugs are due to rising production costs, can not be normal supply, production line transformation, production line stop and other reasons leading to production stoppage, 28 drugs are due to the price or shortage of raw materials led to production, 15 drugs are due to the winning bid price and cost upside down lead to production stoppage.
May 21, Shanxi Province, the centralized bidding procurement network issued two consecutive notices, Chenxin Pharmaceutical Co., Ltd., Chengdu Teo Pharmaceutical Group Co., Ltd. and other 25 pharmaceutical production enterprises 66 product regulations, apply to revoke the direct hanging network product platform registration qualification.
according to the "Notice" shows that the relevant pharmaceutical companies also provide a unified national commitment not to supply, related products will gradually withdraw from the national pharmaceutical market.
it is understood that once the drug scrapping, withdrawal of the network means that will exit the market, lost the original market share, its cost is naturally not small.
In addition, in accordance with the relevant rules of tendering and credit management, these production enterprises may also be included in the list of unperforming enterprises, and other provinces may abandon such enterprises, these enterprises will continue to participate in the bidding opportunities will become very slim.
why are so many companies risking being included in bad records and exiting the market? Industry insiders say that enterprises to withdraw from the market is also a last-order.
, from the announcement issued in various places, the reasons for drug companies to stop production generally related to raw material prices, production line transformation, environmental pollution and so on.
To this end, industry analysts pointed out that in recent years, in the drug review and approval system reform to encourage drug innovation, with volume procurement squeeze dry intermediate link moisture, cut off the chain of gold sales, consistent evaluation to promote generic drugs clinical replacement of high-priced original research drugs, as well as focus on monitoring and strengthening clinical rational drug use and other policies, China's pharmaceutical market pattern is changing dramatically.
coupled with rising production costs, raw material costs and other prices, many enterprises in the production process appeared in part of the small-scale variety cost upside down phenomenon, so that enterprises are not profitable.
this led to a large number of drugs were abandoned, pharmaceutical companies were forced to abandon the market.
in general, a series of medical reforms will continue to bring great pressure to domestic production enterprises, in the case of quality and price requirements, enterprises will apply for the withdrawal of the network will be more normal.
, it will also bring the pain of de-capacity to China's pharmaceutical industry.
future, for the remaining enterprises, in the face of low-cost drug scrap standards, can only be given a reasonable profit, or do more and reduce costs.